History
A list of downloadable documents created during development.
Review proposal consultation
Lung cancer (non small cell, EGFR mutation positive) - afatinib: Equality impact assessment - guidance development
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: Equality impact assessment - guidance development
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: final appraisal determination
-
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: final appraisal determination document
-
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: evaluation report information
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: evaluation report (PDF 9.96 MB)
Lung cancer (non small cell, EGFR mutation positive) - afatinib: final scope
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: final scope
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: final scope (PDF 104 KB)
Lung cancer (non small cell, EGFR mutation positive) - afatinib: final matrix
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: final matrix
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: final matrix (PDF 111 KB)
Lung cancer (non small cell, EGFR mutation positive) - afatinib: response to consultee and commentator comments on the draft scope and provisional matrix
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: response to consultee and commentator comments on the draft scope and provisional matrix
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: Equality Impact Assessment - scoping
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: Equality Impact Assessment - scoping
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: provisional matrix - (pre referral)
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: provisional matrix - (pre referral)
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: draft scope - (pre referral)
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib: draft scope - (pre referral)
-